Postpartum Depression Resources for Providers and Patients
Experts discuss that Postpartum Support International is an invaluable resource offering education, training, and support to clinicians and families, while emphasizing the importance of strong local specialist networks for warm handoffs and streamlined referrals; combined with routine, repeated screening and proactive follow-up, these practices help reduce stigma and improve timely, compassionate care for perinatal mood disorders throughout pregnancy and postpartum.
Watch
Treatment Options and Monitoring Treatment Response in Postpartum Depression
Experts discuss that recent FDA-approved treatments like zuranolone offer rapid relief for postpartum depression, transforming care by enabling shorter, more effective pharmacologic courses; combined with tailored medication strategies, psychotherapy, and practical support around sleep and feeding, these advances promote comprehensive, individualized management that addresses both clinical symptoms and everyday challenges faced by new mothers
Watch
Treatment Barriers and Key Elements of Successful Treatment Plans in Postpartum Depression
Experts discuss that limited access to qualified prescribers, particularly in underserved areas, remains a major barrier to timely pharmacologic treatment for perinatal mental health, underscoring the need for collaborative care models that combine thoughtful assessment, supportive interventions like sleep and therapy, and ongoing follow-up to ensure individualized, effective management.
Watch
Best Practices for Schizophrenia Management
August 18th 2025Panelists discuss how best practices involve starting with lower doses in older patients, considering long-term tolerability over acute symptom control, and potentially using xanomeline/trospium chloride as first-line treatment even for treatment-naive patients presenting with acute psychosis.
Watch
A Case of a 52-Year-Old Female Patient With Schizophrenia
August 18th 2025Panelists discuss how Lila’s late-onset schizophrenia at age 52 raises diagnostic concerns requiring thorough medical workup, and how her response to olanzapine with sedation and shakiness suggests the need for dose reduction or consideration of alternative treatments such as xanomeline/trospium chloride.
Watch
Managing Postpartum Depression in Clinical Practice
Experts discuss that after a positive screen for perinatal mood or anxiety disorders, timely and compassionate intervention—through trusted resources like Postpartum Support International, thoughtful medication and therapy options, and patient-centered education that addresses stigma and supports shared decision-making—is key to achieving meaningful recovery and improved parent-infant outcomes.
Watch
Improving Patient Communication in Postpartum Depression
Experts discuss that reducing stigma, normalizing mental health conversations from the first prenatal visit, expanding access through integrated and virtual care, and addressing systemic barriers through education, collaboration, and policy reform are all critical strategies for improving the detection and treatment of perinatal mood and anxiety disorders.
Watch
Evolving Schizophrenia Treatment Paradigm
August 11th 2025Panelists discuss how xanomeline/trospium chloride should be positioned as a first-line treatment option rather than waiting for treatment failures, given its superior effect size, comprehensive symptom coverage, and favorable tolerability profile compared with that of traditional antipsychotics.
Watch
Recommendations for Switching to Xanomeline/Trospium Chloride for Patients With Schizophrenia
August 11th 2025Panelists discuss how switching patients to xanomeline/trospium chloride requires different cross-titration strategies depending on whether patients are on “done” medications versus “pines” medications, with special attention to anticholinergic effects when transitioning from sedating antipsychotics.
Watch
Screening and Referral Recommendations in Postpartum Depression
Experts discuss that while standardized screening tools are important for detecting perinatal mood and anxiety disorders, true identification often relies on provider intuition, meaningful dialogue, and cross-specialty collaboration—especially in pediatric settings—to ensure timely support for both parent and child.
Watch
Collaborative Role of Providers for Screening, Diagnosis, and Referrals in Postpartum Depression
Experts discuss that effective management of perinatal mood and anxiety disorders in primary care and obstetrics requires routine screening, clear referral pathways, provider education, and collaborative care to ensure timely diagnosis and treatment.
Watch
Efficacy and Safety of Xanomeline/Trospium Chloride and Experience in Treating Schizophrenia
August 4th 2025Panelists discuss how real-world experience with xanomeline/trospium chloride shows efficacy across all 3 symptom domains with manageable gastrointestinal adverse effects that typically resolve within 2 weeks, requiring slow titration and patient education about empty stomach dosing.
Watch
Xanomeline/Trospium Chloride for Treatment of Schizophrenia
August 4th 2025Panelists discuss how xanomeline/trospium chloride represents a first-in-class medication with a novel muscarinic mechanism that addresses positive, negative, and cognitive symptoms while avoiding typical antipsychotic adverse effects such as movement disorders and prolactin elevation.
Watch
Risk Factors for Postpartum Depression
Experts discuss that while anyone can experience perinatal mood and anxiety disorders, individuals with personal or family mental health histories, recent trauma, or medication changes are at higher risk, and emphasize the critical importance of informed, individualized medication management during pregnancy and lactation to balance risks, prevent undertreatment, and ensure the well-being of both parent and child.
Watch
Impact on Quality of Life in Postpartum Depression
Experts discuss how perinatal mental health disorders can significantly impact not only the birthing individual but also parenting capacity, partner relationships, and child development, emphasizing the need for a holistic, trauma-informed, and family-centered approach that addresses the mental health needs of both parents, supports household well-being, and mitigates long-term risks for children.
Watch
A Case of a 24-Year-Old Man With Schizophrenia
July 28th 2025Panelists discuss how Jacob’s case demonstrates the importance of recognizing negative symptoms that preceded positive symptoms by nearly a year, and how a partial response to risperidone with continued breakthrough symptoms and cognitive “fogginess” indicates the need for treatment optimization.
Watch